Evaluating the use of Cialis for erectile dysfunction
Actual Use Trial to Switch Tadalafil 5 mg Tablets From Prescription to Over-the-Counter
This study is testing if men can safely choose and use Cialis over the counter for erectile dysfunction with the help of a digital tool.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 2250 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Sanofi Industry-sponsored |
| Locations | 1 site (Salt Lake City, Utah) |
| Trial ID | NCT06805513 on ClinicalTrials.gov |
What this trial studies
This trial assesses whether men can effectively select and use Cialis (tadalafil 5 mg) over the counter for erectile dysfunction. It involves an open-label design where approximately 2,250 participants will complete a health survey assessment to qualify for the treatment phase. The study will last for four months, during which participants will use a digital tool to aid in their treatment. The goal is to determine the appropriateness of self-selection and usage of the medication by participants.
Who should consider this trial
Good fit: Ideal candidates are men aged 18 and older who are interested in using Cialis for erectile dysfunction and can complete the necessary health survey.
Not a fit: Patients living in Massachusetts or those unable to provide valid identification will not benefit from this study.
Why it matters
Potential benefit: If successful, this could provide a convenient and accessible treatment option for men experiencing erectile dysfunction.
How similar studies have performed: Other studies have shown success with over-the-counter treatments for erectile dysfunction, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants will be included in Part II (enrolment phase) if they are: 1. Male or female, 16 years of age or older 2. Living in the US (Since this study will be conducted remotely, it is important to assure that all participants reside in this country.) Participants will be included in Part III (use phase) if they: 1. Are male (sex assigned at birth) 2. Are at least 18 years of age 3. Complete the HSA with a purchase code for Cialis OTC 4. Purchase the study product Exclusion Criteria: Below participants will be excluded from Part II: 1. Participant lives in the state of Massachusetts (Massachusetts state law requires an application to the State Board of Pharmacy in order to get authorization to distribute the study product to participants who live there.) 2. Participant 18 years of age or older is unable or unwilling to show a current government-issued identification (ID) in order to verify identity and age 3. Participant cannot read, speak, and understand English 4. Participant has participated in another health-related market research study, product label study, or clinical trial in the past 12 months 5. Participant has ever participated in a research study about a medicine for erectile dysfunction 6. Participant, or someone else in the household works for a pharmaceutical company 7. Participant, or someone else in the household is a healthcare professional, works as a part of a health care practice, or has been trained as a healthcare professional 8. Participant, or someone else in the household is employed by a market research or advertising company 9. Participant or someone else in the household is employed by PEGUS Research 10. Participants will be told that if they need corrective lenses to read, they must have them when the remote Enrollment Interview is conducted (Part II). If they do not, they will not be allowed to participate. This exclusion will be implemented during the remote Subgroup Identification Interview (SGI) Interview where the participants will be re-screened. 11. Participants who are considered minors, according to the law in the state where they reside, who do not have a parent or guardian present and willing to electronically sign permission to allow the minor to participate in the SGI and Enrollment Interviews. A participant is considered a minor in all states if they are 16-17 years of age. Additionally, participants 18 years of age in Alabama or Nebraska, and participants 18-20 years of age in Mississippi are also considered minors. 12. Participant is not willing or able to attend/participate in the Enrollment Interview remotely 13. Participant, or someone else in the household, has participated in this study (only one member of each household will be allowed to participate) 14. Participant does not provide verbal permission to video record study interviews 15. If necessary to obtain approximately 30% low health literacy (LHL), participants who are not LHL will be screened out Below participants will be excluded from Part III: 1. Participants who were not excluded for DNU conditions in the HSA, but were determined in the Medical Assessment to have any of the DNU conditions listed on the DFL 2. Participants who do not sign the Informed Consent Document (ICD) or if the parent or guardian of a minor does not sign the ICD. (Parent/guardian refusal applies to males who are 18 years of age or older but considered minors in the state where they reside.) 3. Participants who are unwilling to provide contact information 4. Participants who are unwilling or unable to use an eDiary to record the required information 5. Participants who the principal investigator or the Medical Monitor believes should be excluded or removed from further participation in the Use Phase due to safety concerns
Where this trial is running
Salt Lake City, Utah
- Pegus — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Study coordinator: Trial Transparency email recommended (Toll free for US & Canada)
- Email: Contact-US@sanofi.com
- Phone: 800-633-1610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.